Molecular pathology data has provided a rationale for mTOR inhibitor use in patients suffering from PEComa tumors with and without concomitant tuberous sclerosis [17,18,19]. This evidence concerns the gene MTOR and neoplasm with perivascular epithelioid cell differentiation.